October 14, 2013 / 12:48 PM / 6 years ago

Coronado's inflammatory bowel disease treatment fails mid-stage study

Oct 14 (Reuters) - Coronado Biosciences Inc said its treatment for Crohn’s disease, a type of inflammatory bowel disease, failed to meet the main goal of a mid-stage study.

The company said the response rate of patients with moderate-to-severe Crohn’s disease taking the treatment was not different from patients taking the placebo as measured on a clinical scale.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below